Copyright Reports & Markets. All rights reserved.

Global (United States, European Union and China) Antisense and RNAi Therapeutics Market Research Report 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Research Scope
    • 1.2 Major Manufacturers Covered in This Report
    • 1.3 Market Segment by Type
      • 1.3.1 Global Antisense and RNAi Therapeutics Market Size Growth Rate by Type (2019-2025)
      • 1.3.2 RNA Interference
      • 1.3.3 Antisense RNA
    • 1.4 Market Segment by Application
      • 1.4.1 Global Antisense and RNAi Therapeutics Market Share by Application (2019-2025)
      • 1.4.2 Hospital
      • 1.4.3 Clinic
    • 1.5 Study Objectives
    • 1.6 Years Considered

    2 Global Growth Trends

    • 2.1 Production and Capacity Analysis
      • 2.1.1 Global Antisense and RNAi Therapeutics Production Value 2014-2025
      • 2.1.2 Global Antisense and RNAi Therapeutics Production 2014-2025
      • 2.1.3 Global Antisense and RNAi Therapeutics Capacity 2014-2025
      • 2.1.4 Global Antisense and RNAi Therapeutics Marketing Pricing and Trends
    • 2.2 Key Producers Growth Rate (CAGR) 2019-2025
      • 2.2.1 Global Antisense and RNAi Therapeutics Market Size CAGR of Key Regions
      • 2.2.2 Global Antisense and RNAi Therapeutics Market Share of Key Regions
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers

    3 Market Share by Manufacturers

    • 3.1 Capacity and Production by Manufacturers
      • 3.1.1 Global Antisense and RNAi Therapeutics Capacity by Manufacturers
      • 3.1.2 Global Antisense and RNAi Therapeutics Production by Manufacturers
    • 3.2 Revenue by Manufacturers
      • 3.2.1 Antisense and RNAi Therapeutics Revenue by Manufacturers (2014-2019)
      • 3.2.2 Antisense and RNAi Therapeutics Revenue Share by Manufacturers (2014-2019)
      • 3.2.3 Global Antisense and RNAi Therapeutics Market Concentration Ratio (CR5 and HHI)
    • 3.3 Antisense and RNAi Therapeutics Price by Manufacturers
    • 3.4 Key Manufacturers Antisense and RNAi Therapeutics Plants/Factories Distribution and Area Served
    • 3.5 Date of Key Manufacturers Enter into Antisense and RNAi Therapeutics Market
    • 3.6 Key Manufacturers Antisense and RNAi Therapeutics Product Offered
    • 3.7 Mergers & Acquisitions, Expansion Plans

    4 Market Size by Type

    • 4.1 Production and Production Value for Each Type
      • 4.1.1 RNA Interference Production and Production Value (2014-2019)
      • 4.1.2 Antisense RNA Production and Production Value (2014-2019)
    • 4.2 Global Antisense and RNAi Therapeutics Production Market Share by Type
    • 4.3 Global Antisense and RNAi Therapeutics Production Value Market Share by Type
    • 4.4 Antisense and RNAi Therapeutics Ex-factory Price by Type

    5 Market Size by Application

    • 5.1 Overview
    • 5.2 Global Antisense and RNAi Therapeutics Consumption by Application

    6 Production by Regions

    • 6.1 Global Antisense and RNAi Therapeutics Production (History Data) by Regions 2014-2019
    • 6.2 Global Antisense and RNAi Therapeutics Production Value (History Data) by Regions
    • 6.3 United States
      • 6.3.1 United States Antisense and RNAi Therapeutics Production Growth Rate 2014-2019
      • 6.3.2 United States Antisense and RNAi Therapeutics Production Value Growth Rate 2014-2019
      • 6.3.3 Key Players in United States
      • 6.3.4 United States Antisense and RNAi Therapeutics Import & Export
    • 6.4 European Union
      • 6.4.1 European Union Antisense and RNAi Therapeutics Production Growth Rate 2014-2019
      • 6.4.2 European Union Antisense and RNAi Therapeutics Production Value Growth Rate 2014-2019
      • 6.4.3 Key Players in European Union
      • 6.4.4 European Union Antisense and RNAi Therapeutics Import & Export
    • 6.5 China
      • 6.5.1 China Antisense and RNAi Therapeutics Production Growth Rate 2014-2019
      • 6.5.2 China Antisense and RNAi Therapeutics Production Value Growth Rate 2014-2019
      • 6.5.3 Key Players in China
      • 6.5.4 China Antisense and RNAi Therapeutics Import & Export
    • 6.6 Rest of World
      • 6.6.1 Japan
      • 6.6.2 Korea
      • 6.6.3 India
      • 6.6.4 Southeast Asia

    7 Antisense and RNAi Therapeutics Consumption by Regions

    • 7.1 Global Antisense and RNAi Therapeutics Consumption (History Data) by Regions
    • 7.2 United States
      • 7.2.1 United States Antisense and RNAi Therapeutics Consumption by Type
      • 7.2.2 United States Antisense and RNAi Therapeutics Consumption by Application
    • 7.3 European Union
      • 7.3.1 European Union Antisense and RNAi Therapeutics Consumption by Type
      • 7.3.2 European Union Antisense and RNAi Therapeutics Consumption by Application
    • 7.4 China
      • 7.4.1 China Antisense and RNAi Therapeutics Consumption by Type
      • 7.4.2 China Antisense and RNAi Therapeutics Consumption by Application
    • 7.5 Rest of World
      • 7.5.1 Rest of World Antisense and RNAi Therapeutics Consumption by Type
      • 7.5.2 Rest of World Antisense and RNAi Therapeutics Consumption by Application
      • 7.5.1 Japan
      • 7.5.2 Korea
      • 7.5.3 India
      • 7.5.4 Southeast Asia

    8 Company Profiles

    • 8.1 Tekmira Pharmaceuticals
      • 8.1.1 Tekmira Pharmaceuticals Company Details
      • 8.1.2 Company Description and Business Overview
      • 8.1.3 Production and Revenue of Antisense and RNAi Therapeutics
      • 8.1.4 Antisense and RNAi Therapeutics Product Introduction
      • 8.1.5 Tekmira Pharmaceuticals Recent Development
    • 8.2 Arbutus Biopharma
      • 8.2.1 Arbutus Biopharma Company Details
      • 8.2.2 Company Description and Business Overview
      • 8.2.3 Production and Revenue of Antisense and RNAi Therapeutics
      • 8.2.4 Antisense and RNAi Therapeutics Product Introduction
      • 8.2.5 Arbutus Biopharma Recent Development
    • 8.3 Alnylam Pharmaceuticals
      • 8.3.1 Alnylam Pharmaceuticals Company Details
      • 8.3.2 Company Description and Business Overview
      • 8.3.3 Production and Revenue of Antisense and RNAi Therapeutics
      • 8.3.4 Antisense and RNAi Therapeutics Product Introduction
      • 8.3.5 Alnylam Pharmaceuticals Recent Development
    • 8.4 Antisense Therapeutics
      • 8.4.1 Antisense Therapeutics Company Details
      • 8.4.2 Company Description and Business Overview
      • 8.4.3 Production and Revenue of Antisense and RNAi Therapeutics
      • 8.4.4 Antisense and RNAi Therapeutics Product Introduction
      • 8.4.5 Antisense Therapeutics Recent Development
    • 8.5 Silence Therapeutics
      • 8.5.1 Silence Therapeutics Company Details
      • 8.5.2 Company Description and Business Overview
      • 8.5.3 Production and Revenue of Antisense and RNAi Therapeutics
      • 8.5.4 Antisense and RNAi Therapeutics Product Introduction
      • 8.5.5 Silence Therapeutics Recent Development
    • 8.6 Isis Pharmaceuticals
      • 8.6.1 Isis Pharmaceuticals Company Details
      • 8.6.2 Company Description and Business Overview
      • 8.6.3 Production and Revenue of Antisense and RNAi Therapeutics
      • 8.6.4 Antisense and RNAi Therapeutics Product Introduction
      • 8.6.5 Isis Pharmaceuticals Recent Development
    • 8.7 Sirnaomics
      • 8.7.1 Sirnaomics Company Details
      • 8.7.2 Company Description and Business Overview
      • 8.7.3 Production and Revenue of Antisense and RNAi Therapeutics
      • 8.7.4 Antisense and RNAi Therapeutics Product Introduction
      • 8.7.5 Sirnaomics Recent Development
    • 8.8 Santaris
      • 8.8.1 Santaris Company Details
      • 8.8.2 Company Description and Business Overview
      • 8.8.3 Production and Revenue of Antisense and RNAi Therapeutics
      • 8.8.4 Antisense and RNAi Therapeutics Product Introduction
      • 8.8.5 Santaris Recent Development
    • 8.9 Roche
      • 8.9.1 Roche Company Details
      • 8.9.2 Company Description and Business Overview
      • 8.9.3 Production and Revenue of Antisense and RNAi Therapeutics
      • 8.9.4 Antisense and RNAi Therapeutics Product Introduction
      • 8.9.5 Roche Recent Development

    9 Market Forecast

    • 9.1 Global Market Size Forecast
      • 9.1.1 Global Antisense and RNAi Therapeutics Capacity, Production Forecast 2019-2025
      • 9.1.2 Global Antisense and RNAi Therapeutics Production Value Forecast 2019-2025
    • 9.2 Market Forecast by Regions
      • 9.2.1 Global Antisense and RNAi Therapeutics Production and Value Forecast by Regions 2019-2025
      • 9.2.2 Global Antisense and RNAi Therapeutics Consumption Forecast by Regions 2019-2025
    • 9.3 United States
      • 9.3.1 Production and Value Forecast in United States
      • 9.3.2 Consumption Forecast in United States
    • 9.4 European Union
      • 9.4.1 Production and Value Forecast in European Union
      • 9.4.2 Consumption Forecast in European Union
    • 9.5 China
      • 9.5.1 Production and Value Forecast in China
      • 9.5.2 Consumption Forecast in China
    • 9.6 Rest of World
      • 9.6.1 Japan
      • 9.6.2 Korea
      • 9.6.3 India
      • 9.6.4 Southeast Asia
    • 9.7 Forecast by Type
      • 9.7.1 Global Antisense and RNAi Therapeutics Production Forecast by Type
      • 9.7.2 Global Antisense and RNAi Therapeutics Production Value Forecast by Type
    • 9.8 Consumption Forecast by Application

    10 Value Chain and Sales Channels Analysis

    • 10.1 Value Chain Analysis
    • 10.2 Sales Channels Analysis
      • 10.2.1 Antisense and RNAi Therapeutics Sales Channels
      • 10.2.2 Antisense and RNAi Therapeutics Distributors
    • 10.3 Antisense and RNAi Therapeutics Customers

    11 Opportunities & Challenges, Threat and Affecting Factors

    • 11.1 Market Opportunities
    • 11.2 Market Challenges
    • 11.3 Porter's Five Forces Analysis

    12 Key Findings

      13 Appendix

      • 13.1 Research Methodology
        • 13.1.1 Methodology/Research Approach
          • 13.1.1.1 Research Programs/Design
          • 13.1.1.2 Market Size Estimation
          • 13.1.1.3 Market Breakdown and Data Triangulation
        • 13.1.2 Data Source
          • 13.1.2.1 Secondary Sources
          • 13.1.2.2 Primary Sources
      • 13.2 Author Details

      The rising incidence of coronary artery diseases, cardiac ailments, and neurodegenerative and infectious diseases has led to the demand for antisense and RNai therapeutics. The market exhibits a strong pipeline of product and is looking forward to introduce several advancements in the RNAi drug delivery technology.
      The potential commercialization of a few candidates under research and development will help the antisense and RNAi therapeutics market to pick up pace in North America in the near future.
      In 2019, the market size of Antisense and RNAi Therapeutics is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
      In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Antisense and RNAi Therapeutics.

      This report studies the global market size of Antisense and RNAi Therapeutics, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
      This study presents the Antisense and RNAi Therapeutics production, revenue, market share and growth rate for each key company, and also covers the breakdown data (production, consumption, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
      For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

      In global market, the following companies are covered:
      Tekmira Pharmaceuticals
      Arbutus Biopharma
      Alnylam Pharmaceuticals
      Antisense Therapeutics
      Silence Therapeutics
      Isis Pharmaceuticals
      Sirnaomics
      Santaris
      Roche

      Market Segment by Product Type
      RNA Interference
      Antisense RNA

      Market Segment by Application
      Hospital
      Clinic

      Key Regions split in this report: breakdown data for each region.
      United States
      China
      European Union
      Rest of World (Japan, Korea, India and Southeast Asia)

      The study objectives are:
      To analyze and research the Antisense and RNAi Therapeutics status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
      To present the key Antisense and RNAi Therapeutics manufacturers, presenting the sales, revenue, market share, and recent development for key players.
      To split the breakdown data by regions, type, companies and applications
      To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
      To identify significant trends, drivers, influence factors in global and regions
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

      In this study, the years considered to estimate the market size of Antisense and RNAi Therapeutics are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      Buy now